Table E4.
Variables explaining evolution of PaO2/FiO2
| Variable | β coefficient | P value | 95% CI |
|---|---|---|---|
| Baseline PaO2/FiO2 | 0.713 | <.001 | 0.567 to 0.753 |
| Lymphocyte count | 0.033 | <.001 | 0.015 to 0.052 |
| Hypertension | −19.059 | .067 | −39.432 to 1.314 |
| LDH | −0.101 | .001 | −0.163 to −0.039 |
| CRP | −1.188 | .038 | −2.311 to 0.065 |
| Radiologic findings | |||
| Clear | Reference | ||
| Diffuse ground glass opacities | 49.256 | .006 | 13.785 to 84.727 |
| Unilateral alveolar pattern | 31.638 | .131 | −9.378 to 72.654 |
| Bilateral alveolar pattern | 60.708 | .001 | 25.986 to 95.431 |
| Others | −123.818 | .113 | −276.853 to 29.217 |
| IL-6 serum/TCZ∗ | |||
| Low IL-6, no TCZ | Reference | ||
| Low IL-6, early TCZ | −38.854 | .048 | −77.390 to −0.319 |
| Low IL-6, late TCZ | −40.150 | .019 | −73.765 to −6.535 |
| High IL-6, no TCZ | −16.513 | .279 | −46.440 to 13.413 |
| High IL-6, early TCZ | −8.134 | .672 | −45.831 to 29.562 |
| High IL-6, late TCZ | −38.359 | .021 | −70.837 to −5.881 |
∗
IL-6 serum/TCZ: refers to the interaction between both high or low IL-6 (cutoff 30 pg/mL) and TCZ (no treatment, early or late treatment; cutoff 11 d since symptom onset) as an independent predictor within the model.